

1 Systematic investigations of COVID-19 in 283 cancer patients

2 Jie Wang^{1*}, Qibin Song^{2*}, Yuan Chen^{3*}, Zhijie Wang^{1*}, Qian Chu^{3*}, Hongyun Gong^{2*},
3 Shangli Cai^{4*}, Xiaorong Dong⁵, Bin Xu², Weidong Hu⁶, Qun Wang⁷, Linjun Li⁸, Jiyuan
4 Yang⁹, Zhibin Xie¹⁰, Zhiguo Luo¹¹, Jing Liu¹², Xiuli Luo¹³, Jie Ren¹⁴, Zhiguo Rao¹⁵,
5 Xinhua Xu¹⁶, Dongfeng Pan¹⁷, Zuowei Hu¹⁸, Gang Feng¹⁹, Chiding Hu²⁰, Liqiong Luo²¹,
6 Hongda Lu²², Ruizhi Ran²³, Jun Jin²⁴, Yanhua Xu²⁵, Yong Yang²⁶, Zhihong Zhang²⁷, Li
7 Kuang²⁸, Runkun Wang²⁹, Youhong Dong³⁰, Jianhai Sun³¹, Wenbing Hu³², Tienan Yi³³,
8 Hanlin Wu³⁴, Mingyu Liu³⁵, Jiachen Xu¹, Jianchun Duan¹, Zhengyi Zhao³⁶, Guoqiang
9 Wang⁴, Yu Xu³⁶, Jie He³⁷

10

11 Affiliations:

12 ¹State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National
13 Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese
14 Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China,
15 ²Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China,
16 ³Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University
17 of Science and Technology, Wuhan, Hubei 430030, China, ⁴Burning Rock Biotech,
18 Guangzhou 510300, China, ⁵Cancer Center, Union Hospital, Tongji Medical College,
19 Huazhong University of Science and Technology, Wuhan, Hubei 430022, China,
20 ⁶Department of thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei
21 430071, China, ⁷Department of Oncology, The Fifth Hospital of Wuhan, Wuhan, Hubei
22 430050, China, ⁸Department of Oncology, Hubei Provincial Hospital of Integrated Chinese
23 and Western Medicine, Wuhan, Hubei 430071, China, ⁹Department of Oncology, First
24 Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434023, China, ¹⁰Department
25 of Respiratory and Critical Care Medicine, Xiaogan Hospital Affiliated to Wuhan
26 University of Science and Technology, Xiaogan, Hubei 432100, China, ¹¹Department of
27 Oncology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China,
28 ¹²Department of Oncology, Huanggang Central Hospital, Huanggang, Hubei 438000,
29 China, ¹³Department of Oncology, Hubei Provincial Hospital of TCM, Wuhan, Hubei
30 430000, China, ¹⁴Department of Medical Oncology, General Hospital of The Yangtze River
31 Shipping, Wuhan, Hubei 430010, China, ¹⁵Department of Oncology, General Hospital of
32 Central Theater Command, People's Liberation Army, Wuhan, Hubei 430070, China,
33 ¹⁶Department of Oncology, Yichang Central People's Hospital, Yichang, Hubei 443003,
34 China, ¹⁷Department of Oncology, Suizhou Hospital, HuBei University of Medicine,
35 Suizhou, Hubei 441300, China, ¹⁸Department of Oncology, Wuhan No.1 Hospital, Wuhan,
36 Hubei 430022, China, ¹⁹Department of Oncology, Wuhan Fourth Hospital (Puai Hospital),
37 Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei
38 430000, China, ²⁰Department of Oncology, Affiliated Hospital of Jiangnan University,
39 Wuhan, Hubei 430015, China, ²¹Department of Oncology, Tianyou Hospital Affiliated to
40 Wuhan University of Science and Technology, Wuhan, Hubei 430064, China,
41 ²²Department of Oncology, The Central Hospital of Wuhan, Tongji Medical College,
42 Huazhong University of Science and Technology, Wuhan, Hubei 430014, China,
43 ²³Department of Oncology, The Central Hospital of Enshi Tujia and Miao Autonomous
44 Prefecture, Enshi, Hubei 445000, China, ²⁴Department of Oncology, Ezhou Central
45 Hospital, Ezhou, Hubei 436000, China, ²⁵Department of Oncology, Jingzhou Central
46 Hospital, Jingzhou, Hubei 434020, China, ²⁶Department of oncology, The Second Hospital

47 of WISCO (Wuhan Iron and Steel Corporation), Wuhan, Hubei 430085, China,
48 ²⁷Department of Oncology, Gong'an County People's Hospital, Jingzhou, Hubei 434300,
49 China, ²⁸Department of Oncology, Affiliated Dongfeng Hospital, Hubei University of
50 Medicine, Shiyan, Hubei 442008, China, ²⁹Department of oncology, The first people's
51 hospital of Guangshui, Suizhou, Hubei 432700, China, ³⁰Department of oncology,
52 Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, Hubei
53 441000, China, ³¹Department of Oncology, Hubei No.3 People's Hospital, Wuhan, Hubei
54 430033, China, ³²Department of Oncology, Huangshi Central Hospital of EDong
55 Healthcare, Huangshi, Hubei 435000, China, ³³Department of Oncology, Xiangyang
56 Central Hospital, Hubei Univeristy of Medicine, Xiangyang, Hubei 441021, China,
57 ³⁴Department of Oncology, The First People's Hospital of Jingmen, Jingmen, Hubei
58 448000, China, ³⁵The No. 9 hospital of Wuhan, Wuhan, Hubei 430081, China, ³⁶The
59 Medical Department, 3D Medicines, Inc., Shanghai 201114, China, ³⁷State Key Laboratory
60 of Molecular Oncology, Department of Thoracic Surgery, National Cancer Center/National
61 Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical
62 Sciences & Peking Union Medical College, Beijing 100021, China

63

64 *Contributed equally.

65

66 **Correspondence to:**

67 Jie He, M.D., State Key Laboratory of Molecular Oncology, Department of Thoracic
68 Surgery, National Cancer Center/ National Clinical Research Center for Cancer/Cancer
69 Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing,
70 China, 17 Pan-jia-yuan South Lane, Chaoyang District, 100021, Beijing, China.
71 hejie@cicams.ac.cn; Tel: 86-1087788207;

72

73 Jie Wang, M.D., Ph.D., State Key Laboratory of Molecular Oncology, Department of
74 Medical Oncology, National Cancer Center/National Clinical Research Center for
75 Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical
76 College, Beijing, China, 17 Pan-jia-yuan South Lane, Chaoyang District, 100021, Beijing,
77 China. zlhuxi@163.com; Tel: 86-13910704669.

78

79

80 **Abstracts**

81 **Background:** Cancer patients are considered to be highly susceptible to viral infections,
82 however, the comprehensive features of COVID-19 in these patients remained largely
83 unknown. The present study aimed to assess the clinical characteristics and outcomes of
84 COVID-19 in a large cohort of cancer patients.

85 **Design, Setting, and Participants:** Data of consecutive cancer patients admitted to 33
86 designated hospitals for COVID-19 in Hubei province, China from December 17, 2019 to
87 March 18, 2020 were retrospectively collected. The follow-up cutoff date was April 02,
88 2020. The clinical course and survival status of the cancer patients with COVID-19 were
89 measured, and the potential risk factors of severe events and death were assessed through
90 univariable and multivariable analyses.

91 **Results:** A total of 283 laboratory confirmed COVID-19 patients (50% male; median age,
92 63.0 years [IQR, 55.0 to 70.0]) with more than 20 cancer types were included. The overall
93 mortality rate was 18% (50/283), and the median hospitalization stay for the survivors was
94 26 days. Amongst all, 76 (27%) were former cancer patients with curative resections for
95 over five years without recurrence. The current cancer patients exhibited worse outcomes
96 versus former cancer patients (overall survival, HR=2.45, 95%CI 1.10 to 5.44, log-rank
97 $p=0.02$; mortality rate, 21% vs 9%). Of the 207 current cancer patients, 95 (46%) have
98 received recent anti-tumor treatment, and the highest mortality rate was observed in the
99 patients receiving recent chemotherapy (33%), followed by surgery (26%), other anti-
100 tumor treatments (19%), and no anti-tumor treatment (15%). In addition, a higher mortality
101 rate was observed in patients with lymphohematopoietic malignancies (LHM) (53%, 9/17),
102 and all seven LHM patients with recent chemotherapy died. Multivariable analysis
103 indicated that LHM ($p=0.001$) was one of the independent factors associating with critical
104 illness or death.

105 **Conclusions:** This is the first systematic study comprehensively depicting COVID-19 in a
106 large cancer cohort. Patients with tumors, especially LHM, may have poorer prognosis of
107 COVID-19. Additional cares are warranted and non-emergency anti-tumor treatment
108 should be cautiously used for these patients under the pandemic.

109

110 **Introduction**

111 Since the publicly reported coronavirus disease 2019 (COVID-19) caused by severe acute
112 respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in December, 2019¹ and the
113 subsequent evidences of its human-to-human transmission property released in January
114 2020,² there has been an extremely rapid spread of the novel coronavirus around the globe.
115 The World Health Organization (WHO) has declared a global health emergency on January
116 30, 2020.³ The first systematic description of the clinical characteristics of COVID-19 in
117 China was reported on February, 2020, showing a fatality rate of 1.4% among the 1,099
118 Chinese patients.⁴ Till April 02, 2020, the novel viral infection has caused 82,735 and
119 855,446 cumulative cases in China and worldwide, with 3,327 and 43,955 reported death,
120 respectively.⁵

121 Cancer patients, as a special population who usually have a high demand for
122 intensive care and are frequently systematically immunosuppressed, are considered to be
123 more susceptible to the infection.⁶ Accordingly, a considerable amount of cancer patients
124 may have been subjected to COVID-19 during the pandemic, which has attracted
125 increasing attention from the clinicians.⁶⁻⁹ Recent studies with small cohorts (n = 12 to 28)
126 of SARS-CoV-2 infected cancer patients have proposed the potentially higher
127 susceptibility and poorer prognosis of COVID-19 in cancer patients compared to the
128 overall population.^{6,8,10} However, the study population in these reports are too limited to
129 provide conclusive evidences, and the characteristics of COVID-19 in cancer patients
130 remained largely unknown. Herein, we carried out the present large retrospective study for
131 the comprehensive investigation of the clinical characteristics, prognosis, survival status,
132 and potential risk factors of severe events of COVID-19 in a large cohort of Chinese cancer
133 patients.

134

135 **Methods**

136 **Study Population, Setting and Data Collection**

137 Consecutive cancer patients who were newly admitted to 33 designated hospitals for
138 COVID-19 in Hubei province, China between December 17, 2019 and March 18, 2020
139 were included. The follow-up cutoff date was April 02, 2020. The patients were admitted
140 to the hospitals for suspicious or confirmed SARS-CoV-2 infection irrespective of their on-
141 admission symptom levels, and all patients eventually got laboratory confirmed diagnosis
142 with COVID-19. The collection and tests of clinical specimens, diagnosis, treatment (anti-
143 tumor and anti-infections), examinations, and severity level assessment (asymptomatic,
144 mild, moderate, severe, and critical cases) of COVID-19 were performed following the
145 latest edition of Novel Coronavirus Pneumonia Diagnosis and Treatment Plan released by
146 the National Health Commission & National Administration of Traditional Chinese
147 Medicine by assessment. Nasopharyngeal swabs were collected for pathogenic test using
148 RT-PCR assay to confirm the presence of 2019-nCoV nucleic acid.

149 Data of the demographic and clinicopathological characteristics, infection
150 symptoms, examination results (laboratory tests, chest CT scan, etc.), clinical treatments,
151 and survival outcomes were retrospectively collected from the electronic medical records
152 and further reviewed and confirmed by two independent physicians from each hospital.
153 The data were analyzed by two independent statisticians (GW and YuXu). All
154 inconsistencies were reviewed and confirmed by the Medical Review Board composed of
155 physicians from departments of oncology, thoracic surgery, and pulmonary and critical care
156 medicine. Patient identity protection was maintained throughout the study.

157 **Study Definitions**

158 Former cancer patients were defined as the patients who were diagnosed with malignancies
159 and have received curative surgical resections over five years without recurrence till the
160 hospital admission for COVID-19. Fever was defined as an axillary temperature of 37.5°C
161 or higher. Acute respiratory distress syndrome (ARDS) was defined based on the interim
162 guidance for the management of critical COVID-19 by WHO.¹¹ Recent anti-tumor
163 treatment were defined as the conventional anti-tumor treatment that were provided within
164 3 months before the hospital admission for COVID-19. The types of conventional anti-
165 tumor treatment included: surgical resection, chemotherapy, radiotherapy, targeted therapy,
166 immunotherapy, and combinational therapy, etc. Critical cases were defined as patients
167 with ARDS and requiring mechanical ventilation or extracorporeal membrane oxygenation
168 (ECMO), shock, acute heart failure, acute myocardial infarction, or acute renal failure.
169 Hospitalization stay was defined as the date from hospital admission for COVID-19 till
170 discharge. Remission was defined as either the decrease of at least one-level on disease
171 severity, the change of nucleic acid test results from positive to negative, or the improved
172 absorption of inflammation upon pulmonary imaging. The overall survival (OS) was
173 defined as the time from the date of first clinical visit for suspicious infection of SARS-
174 CoV-2 until death due to any cause.

175 **Statistical Analysis**

176 The clinical pathological variables, symptoms, and chest CT scan results in the patients
177 were statistically described. Continuous variables were described by median (IQR) and
178 categorical variables were described by number (percentages). To assess the differences
179 between different subset of population, Mann-Whitney test was performed for continuous
180 variables and chi-square test was performed for categorical variables. For hospitalization
181 stay, Kaplan-Meier curves were plotted and compared by using a log-rank test with

182 hazard's ratio determined by cox regression. Univariable and multivariable logistic
183 regression were used to test the associations between different variables and the critical
184 and death cases. For univariable analysis, baseline characteristics were tested with blood
185 biochemistry variables transformed into categorical variables with the cutoffs upon the
186 clinical relevance. Variables that achieved a significant level with $p < 0.05$ and an odds
187 ratio (OR) > 3 in the univariable analysis were selected for multivariable logistic regression
188 using stepwise forward conditional mode. When strong correlations were present among
189 the variables that met the above criteria, only the one with the highest odds ratio entered
190 the multivariable analysis. All reported p values were two-tailed, and $p < 0.05$ was
191 considered statistically significant. The analyses were performed with the use of R software
192 (version 3.5.0, R Foundation for Statistical Computing) and GraphPad Prism software
193 (version 5.0, GraphPad Software Inc.).

194 **Results**

195 **Clinical Characteristics**

196 A total of 283 cancer patients who were admitted to 33 designated hospitals with laboratory
197 confirmed diagnosis of COVID-19 were included in the study (**Table 1**). The median age
198 of the overall patients was 63.0 (IQR, 55.0-70.0) years, and 50% were male patients. The
199 overall population harbored more than 20 types of tumor, including 51 (18%) with lung
200 cancer, 38 (13%) with breast cancer, and 34 (12%) with colorectal cancer, etc. The most
201 common comorbidities were hypertension (33%), diabetes (14%), and cardiovascular
202 disease (11%). At onset of illness, 6 (2%), 97 (34%), 108 (38%), and 72 (25%) of the
203 patients were asymptomatic, with mild, moderate, and severe symptoms, respectively.
204 Amongst all, 76 (27%) were former cancer patients who have undergone primary resection
205 for over five years without relapse, 207 (73%) were current cancer patients, including 101

206 (49%) with locally advanced or advanced diseases. Compared with the former cancer
207 patients, the current cancer patients were more likely to exhibit severe symptoms (29% vs
208 17%) on admission.

209 The most common symptoms on admission were fever (73%), cough (68%), fatigue
210 (49%), sputum (41%), and dyspnea (40%) (supplementary table S1). Baseline chest CT
211 scan presented ground glass opacity in 211 (75%) patients, interstitial thickening in 112
212 (40%) patients, consolidation in 71 (25%) patients, and reticular pattern in 60 (21%)
213 patients, which was similarly observed in the former and current cancer patients
214 (supplementary table S2).

215 **Prognosis and outcomes**

216 For treatment against COVID-19, antiviral, antibacterial, hormone, and immunoglobulin
217 therapies were provided for 262 (93%), 233 (82%), 113 (40%), and 86 (30%) patients,
218 respectively. The clinical courses of the patients throughout hospitalization were provided
219 for the overall population (figure 1), the former cancer patients (supplementary figure S1),
220 and the current cancer patients (supplementary figure S2). The overall mortality rate was
221 18% (50/283), including 17% (47/283) deaths due to COVID-19. During hospitalization,
222 19 mild cases, 34 moderate cases, and 72 severe cases eventually developed severe (62
223 [22%]) and critical (63 [22%]) cases. Of the critical cases, 45 (71%) died by the last visit,
224 accounting for 90% of the overall death cases (figure 1). The most common complications
225 were ARDS (85, 30%), stroke (42, 15%), and acute heart failure (17, 6%). Non-invasive
226 and invasive mechanical ventilations were provided for 51 (18%) and 18 (6%) patients,
227 respectively. At the last follow up, there were 178 (63%) asymptomatic cases and 2 (1%)
228 severe cases (figure 1).

229 The illustration of the clinical evaluations and outcomes of the patients with
230 different types of cancer is provided in figure 2. The remission rate was 81% in the overall
231 patients, 91% (69/76) in the former cancer patients, and 78% (161/207) in the current
232 cancer patients, respectively. The recovery degree as represented by the ratio of
233 asymptomatic patients by the last follow-up visit was 63% (178/283) in the overall
234 population, 68% (52/76) in the former cancer patients, and 61% (126/207) in the current
235 cancer patients, respectively. As shown, the worst prognosis was observed in the patients
236 with current lymphohematopoietic malignancies (LHM) including lymphoma (n = 8) and
237 leukemia (n = 9), followed by esophageal cancer (n = 9) and lung cancer (n = 51), with
238 a remission rate of 38%, 44%, 67%, and 70%, and a degree of recovery of 38%, 22%, 44%,
239 and 54%, respectively (figure 2, supplementary table S3). In addition, the LHM patients
240 were more likely to develop severe or critical cases (59%, 10/17 vs 22%, 41/190) and
241 deaths (53%, 9/17 vs 18%, 34/190) compared to patients with solid tumors (supplementary
242 Table S4), and all the seven LHM patients with recent chemotherapy died.

243 The median hospitalization stay was 24 days for the overall survivors (figure 3A)
244 and the median duration from admission to death was 13.5 days in COVID-19 deceased
245 cases (figure 3B). The current cancer patients exhibited a longer median hospitalization
246 stay (26 days vs 25 days, figure 3C) and significantly higher risk of death compared to the
247 former cancer patients (OS, HR 2.45, 95%CI 1.10-5.44, log-rank $p = .023$), with a mortality
248 rate of 21% (43/207) and 9% (7/76), respectively (figure 3D). Of the 207 current cancer
249 patients, 95 (46%) have received recent anti-tumor treatments, including 46 (22%) with
250 chemotherapy, 23 (11%) with surgical resection, and 26 (13%) with other anti-tumor
251 treatments. Among them, the highest mortality rate was observed in the patients treated
252 with recent chemotherapy (33%), followed by surgery (26%), other treatments (19%), and

253 no treatment (15%) (supplementary figure S3). Two patients have received recent
254 immunotherapy as monotherapy, including one stage IV lung cancer patient with mild
255 symptoms at diagnosis, experienced severe illness during hospitalization, got recovered
256 after treatment and discharged with 31-day hospitalization stay, and another patient with
257 stage IV urothelial cancer who had moderate symptoms as the worst status and got
258 discharged after recovery with 26 days of hospitalization stay.

259 **Risk factors**

260 Logistic regression analyses were conducted to investigate the potential risk factors
261 associated with disease severity in COVID-19 cancer patients. Demographic and clinical
262 characteristics, symptoms, CT findings and laboratory findings were included for analysis.
263 Multivariable analysis indicated that lymphohematopoietic malignancies ($p = 0.001$),
264 severe symptoms at first clinical visit ($p = 0.012$), and elevated levels of neutrophil ($>$
265 $6.3 \times 10^9/\text{mL}$, $p = 3.00 \times 10^{-6}$), direct bilirubin (DBIL) ($> 7 \mu\text{mol/L}$, $p = 0.001$), creatinine
266 ($> 115 \mu\text{M}$, $p = 0.007$), and troponin ($> 5 \text{ ng/ml}$, $p = 0.033$) at baseline were independent
267 risk factors associated with the development of critical illness or deaths (table 2). No
268 significant association was observed between the cancer status (current vs former) with
269 critical or death cases.

270

271 **Discussion**

272 The rapid spreading of COVID-19 has swept the globe, leading to a worldwide pandemic.
273 The present study has provided the first comprehensive depiction of the clinicopathological
274 characteristics, clinical outcomes, and risk factors for death of COVID-19 in patients with
275 tumors. Our study highlighted the poorer prognosis of COVID-19 in cancer patients, which
276 may provide valuable clues for the patient management under the current coronavirus

277 disease pandemic.

278 In our cohort of 283 cancer patients with COVID-19 infection, the median
279 hospitalization stay was 26 days, which is longer than the previously reported 12 days⁴ in
280 the unselected COVID-19 cases and 16 days in the severe cases.¹² Recent study reported
281 that the mortality rate was 28.6% in 28 SARS-CoV-2 infected cancer patients,⁸ our analysis
282 further provided a mortality rate of 18%, with 9% in former cancer patients and 21% in
283 current cancer patients, both higher than that of the overall cumulative mortality rate of
284 COVID-19 cases as reported in Hubei province (4.7%) over the same period (as of April
285 02, 2020),⁵ indicating the worse outcomes in the patients with a history of cancer when
286 infected by the novel coronavirus.

287 A statistically significantly shorter overall survival was observed in the current
288 cancer patients compared to the former cancer patients, and the difference was larger when
289 the patients received recent anti-tumor treatment, especially chemotherapy, which is most
290 likely to weaken the immune system among different treatments. For patients with LHM,
291 who often have a severely defective immune system upon the largely replacement of
292 normal functional immune cells by malignant cells, a higher prevalence was observed in
293 the studied cohort (6.0%, 3.2% for leukemia and 3.5% for lymphoma), which almost
294 doubles that of the prevalence of LHM in the overall cancer population in China (3.8%,
295 1.8% for leukemia and 2.1% for lymphoma),¹³ indicating that these patients may be more
296 susceptible to SARS-CoV-2 infection. In addition, an even higher rate of death cases was
297 observed in patients with LHM (53%) compared with the patients with solid tumors (18%),
298 and all of the LHM patients who were treated with recent chemotherapy died. Collectively,
299 our results further suggested that the worse outcomes in SARS-CoV-2 infected cancer
300 patients may be attributed to both the intrinsic immunocompromised status from the

301 malignancies and the immunosuppression caused by active anti-tumor treatments.
302 Accordingly, anti-tumor treatment, especially chemotherapy, should be used with great
303 caution to reduce the potential negative effects on the patients.

304 Previous reports suggested that age and coexisting conditions were potential risk
305 factors associated with disease severity.¹⁴⁻¹⁶ Given the higher median age in our cancer
306 cohort (63 years) than the reported median age of 47-year-old in the general COVID-19
307 patients, the effect of age on the disease severity was weakened, providing a relatively
308 lower level of significance (OR, 1.94, 95%CI 1.12-3.37) in the univariable analysis
309 compared to the other variables (table 2). Our study further showed that LHM, an elevated
310 baseline neutrophil, DBIL, creatinine, troponin, and the severe symptoms at onset illness
311 were independently associated with the development of critical or death cases in cancer
312 patients with COVID-19, which may provide important implications for the patient cares.

313 There are several limitations in this study. Firstly, this study was conducted in a
314 retrospective setting. Nevertheless, the patient population in this study was relatively large,
315 and the patients were consecutively included irrespective of their baseline characteristics
316 including the clinical symptoms, which will reduce the potential bias of the study
317 population. Secondly, this study focused on the investigation of patients with cancer
318 infected with SARS-CoV-2, and no direct comparison was conducted between the infected
319 cancer patients and the non-cancer patients. Despite that, comparisons have been made
320 between the current and the former cancer patients, who were considered to exhibit
321 relatively more likely to cancer-free patients as a reference. Besides, the studied population
322 came from as many as 33 designated hospitals in Hubei province, China, which is
323 considered to be fairly representative for the overall condition of COVID-19 cancer
324 patients in Hubei province, and thus was compared with the data of general COVID-19

325 patients in Hubei province over the same period.

326

327 **Conclusion**

328 Our study provided the first systematic investigations of the clinical characterization,
329 outcomes, and risk factors for disease severity of COVID-19 patients with malignancies.

330 The results indicated a potentially higher susceptibility and poorer prognosis of patients
331 with a history of cancer when infected with SARS-CoV-2. Given that there are no
332 confirmed effective drugs for the prevention or treatment of COVID-19 to date, strict
333 preventions and special cares are warranted for patients with malignancies to minimize the
334 potential risks and impacts from infections under the pandemic.

335

336 **Contributors:** JW and JH contributed equally to this paper and are joint corresponding
337 authors. JW, QS, YC, ZW, QC, HG, and SC are joint first authors. All corresponding and
338 first authors contributed to study concept and design. JW, ZW, SC, QS, QC, GW, YuXu,
339 and ZZhao contributed to the acquisition, analysis, and interpretation of data. JW, ZW, SC,
340 GW, YuXu, and ZZhao wrote the first draft of the report. All authors approved the final
341 version of the report. JH and JW were responsible for the integrity and accuracy of the data
342 and is the guarantor. The corresponding authors attest that all listed authors meet authorship
343 criteria and that no others meeting the criteria have been omitted.

344 **Funding:** This work was supported by the CAMS Initiative for Innovative Medicine
345 (CAMS 2020-I2M-CoV19-004). The funding sources had no role in the design and conduct
346 of the study; collection, management, analysis, and interpretation of the data; preparation,
347 review, or approval of the manuscript; and decision to submit the manuscript for
348 publication.

349 **Competing interests:** All authors declare no competing interests.

350 **Ethical approval:** This study was approved by the Ethics Committee of the National
351 Cancer Center (No. 20/061-2257, Beijing, China). The requirement for informed patient
352 consent was waived by the ethics committee due to the urgent of data collection.

353 **Data sharing:** The data that support the findings of this study are available from the
354 corresponding author on reasonable request.

355 The manuscript's guarantor affirms that the manuscript is an honest, accurate, and
356 transparent account of the study being reported; that no important aspects of the study have
357 been omitted; and that any discrepancies from the study as planned and registered have
358 been explained.

359 **References**

- 360 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
361 coronavirus in Wuhan, China. *Lancet*. Feb 15 2020;395(10223):497-506.
- 362 2. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel
363 Coronavirus-Infected Pneumonia. *The New England journal of medicine*. Mar 26
364 2020;382(13):1199-1207.
- 365 3. World Health Organization. Coronavirus disease (COVID-19) pandemic. . 2020,
366 2020.
- 367 4. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019
368 in China. *The New England journal of medicine*. Feb 28 2020.
- 369 5. Tencent Epidemic Situation Tracker. 2020, 2020.
- 370 6. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a
371 nationwide analysis in China. *The Lancet. Oncology*. Mar 2020;21(3):335-337.
- 372 7. Wang Z, Wang J, He J. Active and Effective Measures for the Care of Patients with

- 373 Cancer During the COVID-19 Spread in China. *JAMA oncology*. 2020;In press.
- 374 8. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer
375 patients: A retrospective case study in three hospitals within Wuhan, China. *Annals
376 of oncology : official journal of the European Society for Medical Oncology*. Mar
377 26 2020.
- 378 9. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With
379 Cancer at a Tertiary Care Hospital in Wuhan, China. *JAMA oncology*. 2020.
- 380 10. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With
381 Cancer at a Tertiary Care Hospital in Wuhan, China. *JAMA oncology*. Mar 25 2020.
- 382 11. World Health Organization. Clinical management of severe acute respiratory
383 infection when novel coronavirus (nCoV) infection is suspected. Interim guidance.
384 2020.
- 385 12. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized
386 with Severe Covid-19. *The New England journal of medicine*. Mar 18 2020.
- 387 13. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA: a cancer
388 journal for clinicians*. Mar-Apr 2016;66(2):115-132.
- 389 14. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99
390 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
391 *Lancet*. Feb 15 2020;395(10223):507-513.
- 392 15. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients
393 in the Seattle Region - Case Series. *The New England journal of medicine*. Mar 30
394 2020.
- 395 16. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory
396 Distress Syndrome and Death in Patients With Coronavirus Disease 2019

397 Pneumonia in Wuhan, China. *JAMA internal medicine*. Mar 13 2020.

398

399

400 **Table 1. Demographic, clinical, laboratory findings of cancer patients at the first clinical visit.**

	Total (n = 283)	Former cancer patients (n = 76)	Current cancer patients (n = 207)
Demographic and clinical characteristics			
Age	63.0 (55.0-70.0)	65.0 (60.0-73.0)	62.0 (53.0-69.0)
Sex			
Female	142 (50)	45 (59)	97 (47)
Male	141 (50)	31 (41)	110 (53)
Smoking history			
Current	11 (4)	1 (1)	10 (5)
Former	54 (19)	10 (13)	44 (21)
Never	216 (76)	65 (86)	151 (73)
NA	2 (1)	0 (0)	2 (1)
Drinking history			
Current	11 (4)	1 (1)	10 (5)
Former	41 (14)	5 (7)	36 (17)
Never	210 (74)	69 (91)	141 (68)
NA	21 (7)	1 (1)	20 (10)
Huanan market exposure			
No	254 (90)	67 (88)	187 (90)
Yes	10 (4)	4 (5)	6 (3)
NA	19 (7)	5 (7)	14 (7)
Symptoms at the first visit			
Asymptomatic	6 (2)	1 (1)	5 (2)
Mild	97 (34)	26 (34)	71 (34)
Moderate	108 (38)	36 (47)	72 (35)
Severe	72 (25)	13 (17)	59 (29)
Pathology			
Lung cancer	51 (18)	5 (7)	46 (22)
Breast cancer	38 (13)	17 (22)	21 (10)
Colorectal cancer	34 (12)	14 (18)	20 (10)
Thyroid carcinoma	23 (8)	7 (9)	16 (8)
Gastric cancer	18 (6)	5 (7)	13 (6)
Cervical cancer	11 (4)	5 (7)	6 (3)
Leukemia	11 (4)	2 (3)	9 (4)
Urothelial cancer	11 (4)	4 (5)	7 (3)
Lymphoma	10 (4)	2 (3)	8 (4)
Esophageal cancer	9 (3)	0 (0)	9 (4)
Hepatocellular carcinoma	9 (3)	1 (1)	8 (4)
Head and neck cancer	7 (2)	4 (5)	3 (1)
Ovarian cancer	5 (2)	1 (1)	4 (2)
Prostate cancer	5 (2)	1 (1)	4 (2)
Sarcoma	5 (2)	1 (1)	4 (2)
Pancreatic cancer	4 (1)	0 (0)	4 (2)
Renal cell carcinoma	4 (1)	0 (0)	4 (2)
Others	28 (10)	7 (9)	21 (10)
Recent anti-cancer treatment			
No	188 (66)	76 (100)	112 (54)
Surgery	23 (8)	0 (0)	23 (11)

	Chemotherapy	46 (16)	0 (0)	46 (22)
	Targeted therapy	12 (4)	0 (0)	12 (6)
	Others	14 (5)	0 (0)	14 (7)
Diabetes	No	244 (86)	60 (79)	184 (89)
	Yes	39 (14)	16 (21)	23 (11)
Hypertension	No	189 (67)	45 (59)	144 (70)
	Yes	94 (33)	31 (41)	63 (30)
Cardiovascular comorbidity	No	251 (89)	64 (84)	187 (90)
	Yes	32 (11)	12 (16)	20 (10)
Cerebrovascular comorbidity	No	264 (93)	66 (87)	198 (96)
	Yes	19 (7)	10 (13)	9 (4)
COPD	No	263 (93)	75 (99)	188 (91)
	Yes	20 (7)	1 (1)	19 (9)
Chronic liver disease	No	269 (95)	74 (97)	195 (94)
	Yes	14 (5)	2 (3)	12 (6)
Chronic renal disease	No	273 (96)	72 (95)	201 (97)
	Yes	10 (4)	4 (5)	6 (3)
Laboratory findings				
Leukocyte	$\times 10^9/\text{mL}$	5.46 (4.16-7.23)	5.61 (4.53-6.84)	5.37 (3.90-7.26)
Neutrophil	$\times 10^9/\text{mL}$	3.86 (2.59-5.47)	3.81 (2.77-4.84)	3.86 (2.54-5.76)
Lymphocyte	$\times 10^9/\text{mL}$	0.86 (0.57-1.34)	0.98 (0.72-1.54)	0.80 (0.52-1.28)
Monocyte	$\times 10^9/\text{mL}$	0.42 (0.30-0.60)	0.44 (0.37-0.61)	0.39 (0.26-0.59)
Eosinophil	$\times 10^9/\text{mL}$	0.03 (0.00-0.08)	0.05 (0.01-0.09)	0.02 (0.00-0.08)
Basophil	$\times 10^9/\text{mL}$	0.01 (0.01-0.02)	0.01 (0.01-0.02)	0.01 (0.00-0.02)
Platelet	$\times 10^9/\text{mL}$	188 (121-247)	222 (169-272)	179 (104-227)
ALT	U/L	22.0 (13.0-36.8)	22.3 (15.8-33.3)	21.5 (12.0-38.4)
AST	U/L	28.0 (19.0-39.0)	25.0 (19.0-39.0)	28.5 (19.0-39.0)
TBIL	$\mu\text{mol/L}$	10.8 (7.88-14.8)	11.1 (9.35-14.5)	10.5 (7.40-15.0)
DBIL	$\mu\text{mol/L}$	3.70 (2.50-5.43)	3.40 (2.50-4.30)	4.00 (2.60-6.20)
Urea	mM	4.88 (3.62-6.90)	5.00 (4.00-6.23)	4.80 (3.40-7.47)
Creatinine	μM	64.1 (53.0-84.0)	64.5 (55.0-83.8)	64.1 (52.0-84.0)
Prothrombin time	s	12.8 (11.8-13.8)	12.7 (11.6-13.4)	12.8 (11.9-14.0)
APTT	s	33.3 (28.7-38.4)	32.9 (28.4-37.7)	33.5 (28.8-38.6)
D-dimer	$\mu\text{g/mL}$	0.83 (0.36-2.00)	0.57 (0.24-1.54)	0.93 (0.47-2.49)
CK-MB	U/L	1.31 (0.60-6.20)	1.41 (0.90-4.46)	1.12 (0.50-8.00)
Troponin	ng/ml	0.08 (0.01-3.20)	0.02 (0.01-2.20)	1.69 (0.01-3.60)
CRP	mg/L	26.5 (5.82-70.2)	15.8 (5.00-56.0)	29.3 (6.20-72.4)
hsCRP	mg/L	27.1 (5.00-64.3)	22.2 (5.00-56.6)	28.0 (5.00-68.0)
Procalcitonin	ng/mL	0.11 (0.05-0.26)	0.08 (0.03-0.13)	0.12 (0.05-0.34)

401 Data are median (IQR), or n (%). Abbreviations: NA=not applicable; COPD=chronic obstructive pulmonary disease;
 402 ALT=alanine aminotransferase; AST=aspartate aminotransferase; TBIL=total bilirubin. DBIL=direct bilirubin;
 403 APTT=activated partial thromboplastin time; CK-MB=creatinine kinase-MB; CRP=C-reactive protein; hsCRP=high
 404 sensitivity C-reactive protein.


405 **Table 2. Risk factors at the first clinical visit associated with critical ill or death.**

	Comparison	Univariable OR (95%CI)	p value	Multivariable OR (95%CI)	p value
Demographic and clinical characteristics					
Age	year >65 vs. ≤65	1.94 (1.12-3.37)	0.02		
Sex	Female vs. male	0.67 (0.39-1.16)	0.16		
Smoking history	No (ref.)				
	Current vs. ref.	0.78 (0.16-3.72)	0.75		
	Former vs. ref.	1.61 (0.83-3.10)	0.16		
Drinking history	No (ref.)				
	Current vs. ref.	0.75 (0.16-3.59)	0.72		
	Former vs. ref.	1.40 (0.66-2.94)	0.38		
Huanan market exposure	Yes vs. no	0.77 (0.16-3.74)	0.75		
Cancer history	Former (ref.)				
	Current vs. ref.	1.98 (0.99-3.94)	0.052		
	LHM vs. ref.	9.78 (3.03-31.51)	1.34*10 ⁻⁴	40.02 (4.35-368.69)	0.001
	Lung cancer vs. ref.	3.13 (1.32-7.38)	0.009	1.69 (0.32-8.95)	0.54
	Other cancers vs. ref.	1.29 (0.61-2.70)	0.51	1.00 (0.22-4.52)	1.00
Recent anti-cancer treatment	No treatment (ref.)				
	Any treatment vs. ref.	1.93 (1.11-3.38)	0.021		
	Surgery vs. ref.	1.43 (0.53-3.88)	0.48		
	Chemotherapy vs. ref.	2.38 (1.18-4.78)	0.015		
	Others vs. ref.	1.71 (0.69-4.20)	0.24		
Diabetes	Yes vs. no	0.42 (0.16-1.13)	0.085		
Hypertension	Yes vs. no	1.58 (0.90-2.78)	0.11		
Cardiovascular comorbidity	Yes vs. no	2.84 (1.33-6.07)	0.007		
Cerebrovascular comorbidity	Yes vs. no	0.83 (0.27-2.60)	0.75		
COPD	Yes vs. no	2.26 (0.88-5.77)	0.090		
Chronic liver disease	Yes vs. no	0.86 (0.23-3.16)	0.82		
Chronic renal disease	Yes vs. no	0.78 (0.16-3.78)	0.76		
Symptoms					
Symptoms at the first visit	Severe vs. non-severe	5.10 (2.82-9.23)	7.16*10 ⁻⁸	5.43 (1.46-20.24)	0.012
Fever	Yes vs. no	0.77 (0.42-1.42)	0.40		
Cough	Yes vs. no	1.51 (0.82-2.81)	0.19		
Sputum	Yes vs. no	2.12 (1.22-3.70)	0.008		
Dyspnea	Yes vs. no	4.14 (2.31-7.39)	2.00*10 ⁻⁶		
Fatigue	Yes vs. no	1.74 (1.00-3.03)	0.052		
Headache	Yes vs. no	1.53 (0.56-4.19)	0.41		
Muscle ache	Yes vs. no	0.54 (0.20-1.46)	0.22		
Sore throat	Yes vs. no	1.18 (0.36-3.83)	0.79		
Diarrhea	Yes vs. no	0.63 (0.25-1.59)	0.33		
Nausea	Yes vs. no	0.46 (0.13-1.59)	0.22		
Sneeze	Yes vs. no	3.28 (0.45-23.72)	0.24		
Nasal congestion	Yes vs. no	1.07 (0.11-10.47)	0.95		
Nasal discharge	Yes vs. no	1.97 (0.46-8.46)	0.36		
CT findings					
Ground glass opacity	Yes vs. no	0.72 (0.37-1.40)	0.33		

Reticular pattern		Yes vs. no	1.07 (0.55-2.08)	0.85		
Interstitial thickening		Yes vs. no	1.29 (0.73-2.27)	0.38		
Crazy paving appearance		Yes vs. no	1.06 (0.43-2.62)	0.90		
Consolidation		Yes vs. no	2.17 (1.19-3.96)	0.011		
Bronchiectasis		Yes vs. no	2.49 (1.05-5.91)	0.039		
Bilateral involvement		Yes vs. no	1.62 (0.71-3.69)	0.25		
Multicentric pattern		Yes vs. no	1.20 (0.64-2.25)	0.58		
Laboratory findings						
<i>Hematologic indices</i>						
Leukocyte	×10 ⁹ /mL	>9.5 vs. ≤9.5	10.44 (4.75-22.95)	5.23*10 ⁻⁹		
Neutrophil	×10 ⁹ /mL	>6.3 vs. ≤6.3	9.56 (4.87-18.77)	5.42*10 ⁻¹¹	32.77 (7.60-141.26)	3.00*10 ⁻⁶
Lymphocyte	×10 ⁹ /mL	>1.1 vs. ≤1.1	0.34 (0.17-0.66)	0.001		
		>0.5 vs. ≤0.5	0.47 (0.25-0.92)	0.03		
Monocyte	×10 ⁹ /mL	>0.6 vs. ≤0.6	2.95 (1.62-5.37)	4.14*10 ⁻⁴		
Eosinophil	×10 ⁹ /mL	>0.02 vs. ≤0.02	0.19 (0.10-0.36)	0.00E0		
Basophil	×10 ⁹ /mL	>0.06 vs. ≤0.06	1.66 (0.48-5.72)	0.42		
Platelet	×10 ⁹ /mL	>125 vs. ≤125	0.35 (0.19-0.62)	3.94*10 ⁻⁴		
<i>Hepatic function</i>						
ALT	U/L	>40 vs. ≤40	1.47 (0.78-2.79)	0.23		
AST	U/L	>40 vs. ≤40	2.62 (1.43-4.80)	0.002		
TBIL	μmol/L	>17.1 vs. ≤17.1	4.27 (2.17-8.40)	2.55*10 ⁻⁵		
DBIL	μmol/L	>7 vs. ≤7	6.50 (3.25-13.01)	1.20*10 ⁻⁷	14.48 (2.79-75.22)	0.001
<i>Renal function</i>						
Urea	mM	>7.1 vs. ≤7.1	5.24 (2.82-9.72)	1.55*10 ⁻⁷		
Creatinine	μM	>115 vs. ≤115	6.43 (2.75-15.03)	1.72*10 ⁻⁵	23.22 (2.40-224.35)	0.007
<i>Coagulation function</i>						
Prothrombin time	s	>14 vs. ≤14	3.66 (1.92-6.98)	8.17*10 ⁻⁵		
APTT	s	>37 vs. ≤37	1.19 (0.65-2.18)	0.56		
D-dimer	μg/mL	>0.55 vs. ≤0.55	3.40 (1.67-6.94)	0.001		
		>2 vs. ≤2	3.47 (1.86-6.47)	8.80*10 ⁻⁵		
<i>Myocardial injury</i>						
CK-MB	U/L	>0.6 vs. ≤0.6	3.35 (1.33-8.43)	0.010		
		>6 vs. ≤6	2.86 (1.42-5.79)	0.003		
Troponin	ng/ml	>0.1 vs. ≤0.1	1.30 (0.68-2.48)	0.42		
		>5 vs. ≤5	3.56 (1.64-7.71)	0.001	5.57 (1.15-27.10)	0.033
<i>Infection-related indices</i>						
CRP	mg/L	>10 vs. ≤10	5.60 (2.11-14.88)	0.001		
		>100 vs. ≤100	5.92 (2.70-13.01)	9.00*10 ⁻⁶		
hsCRP	mg/L	>5 vs. ≤5	3.38 (1.42-8.06)	0.006		
		>100 vs. ≤100	5.48 (2.25-13.38)	1.87*10 ⁻⁴		
Procalcitonin	ng/mL	>0.1 vs. ≤0.1	3.07 (1.60-5.91)	0.001		
		>0.5 vs. ≤0.5	5.56 (2.54-12.18)	1.82*10 ⁻⁵		

406 *p* values were calculated by univariable or multivariable logistic regression. Abbreviations: NA=not applicable.
 407 COPD=chronic obstructive pulmonary disease. ALT=alanine aminotransferase; AST=aspartate aminotransferase;
 408 TBIL=total bilirubin; DBIL=direct bilirubin; APTT=activated partial thromboplastin time; CK-MB=creatine kinase-MB;
 409 CRP=C-reactive protein; hsCRP=high sensitivity C-reactive protein; LHM= Lymphohematopoietic cancer.
 410

Figure 1




411

412 **Figure 1. Clinical course of the patients in the study.** Clinical evaluations of the patients were
413 shown from their onset illness (left), most severe severity level (middle), to last follow-up visit (right).

414 The patients with different severity levels were demonstrated in different colors.

415


Figure 2



416

417 **Figure 2. Illustration of the multidimensional outcomes of former cancer patients and the**
 418 **current cancer patients with different tumor types with COVID-19.** Each pie represents one group
 419 of current cancer patient with a specific type of cancer, the former cancer patients were illustrated as
 420 a separate group. The y coordinate of each pie center represents the rate of patients with no symptoms
 421 at the last follow-up visit; the x coordinate represents the rate of remission at last follow-up visit; the
 422 composition within each pie represents the distribution of most severe symptom levels in each tumor
 423 type; the size of the pie represents the population size as demonstrated in the inset. Tumors with the
 424 population size less than 10 are not shown in the figure and were considered as “other”.

Figure 3



425

426 **Figure 3. Kaplan-Meier curves of the outcomes of the patients.** (A) Kaplan-Meier curves of the
427 hospitalization stay of the overall survivors. (B) Kaplan-Meier curve of the time to death in COVID-
428 19 deceased cases. (C) Kaplan-Meier curves comparing the hospitalization stay of survivors between
429 the former and current cancer patients. (D) Comparison of the overall survival between the former
430 and the current cancer patients.

431

432